Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors
Beth Eaby-Sandy, MSN, CRNP, OCN®, Carolyn Grande, CRNP, AOCNP®, and Pamela Hallquist Viale, RN, MS, CS, ANP, AOCNP®
From Abramson Cancer Center, Philadelphia, Pennsylvania, and Goleta, California
Ms. Eaby-Sandy has served on the speaker’s bureau for Genentech, Inc., and has acted as a consultant for Amgen, Inc. Ms. Grande has no disclosures to report. Ms. Viale has served on speaker’s bureaus for Merck, Novartis, and Amgen; she has served on advisory boards for Novartis.
Correspondence to: Beth Eaby-Sandy, MSN, CRNP, OCN®, 3400 Civic Center Boulevard, 2nd Floor West, Perelman Center for Advanced Medicine, Philadelphia, PA 19104. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2012;3:138–150 |
DOI: 10.6004/jadpro.2012.3.3.2 |
© 2012 Harborside Press®
Targeted therapies have produced significant treatment advances for patients diagnosed with a variety of tumor types. These therapies are associated with unique dermatologic toxicities that may hamper treatment efforts and cause significant discomfort for patients. Prevention and management of these toxicities can allow patients to remain on therapy and hence receive maximum clinical benefit from the drug.
For access to the full length article, please sign in